Harm Avoidance, Anxiety, and Response to Novelty in the Adolescent S-100β Transgenic Mouse: Role of Serotonin and Relevance to Down Syndrome

S-100 β is an astroglial-derived protein, which plays a role in brain development and maintenance, and is known to play a specific role in the regulation of growth of the serotonergic neuronal system. In humans, the gene for S-100 β is found on chromosome 21, within the region that is considered imp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuropsychopharmacology (New York, N.Y.) N.Y.), 2003-10, Vol.28 (10), p.1810-1816
Hauptverfasser: Bell, Kimberly, Shokrian, David, Potenzieri, Carl, Whitaker-Azmitia, Patricia M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1816
container_issue 10
container_start_page 1810
container_title Neuropsychopharmacology (New York, N.Y.)
container_volume 28
creator Bell, Kimberly
Shokrian, David
Potenzieri, Carl
Whitaker-Azmitia, Patricia M
description S-100 β is an astroglial-derived protein, which plays a role in brain development and maintenance, and is known to play a specific role in the regulation of growth of the serotonergic neuronal system. In humans, the gene for S-100 β is found on chromosome 21, within the region that is considered important for the phenotype of Down syndrome (DS). Thus, we have been studying a model of DS, the S-100 β transgenic mouse. In the current study, we have examined anxiety and responses to novelty in adolescent (60–90 days) animals, at a time when we have shown the animals to be relatively lacking in serotonin innervation, compared to their CD-1 nontransgenic controls. In a test for approach/avoidance, the light/dark test, the S-100 β transgenic mice animals showed no differences from control CD-1 mice. However, in the hole-board test for exploratory behavior, the S-100 β animals were found to be less responsive to the inhibiting effects of the serotonin receptor 5-HT1A agonist, buspirone. Three tests were used to measure response to novelty. In the open field, the S-100 β animals showed greater activity longer than the control animals, and in the Y-maze test, the S-100 β animals spent more time in the novel arm. In a test for novelty-induced gnawing, the S-100 β animals were also more active than control animals. All of these suggest that the S-100 β transgenic mice are slower to habituate to novelty than control animals. Finally, we tested the animals in a new procedure that we are proposing as a test for harm avoidance. In this apparatus, the S-100 β animals showed more approaches to a novel and potentially harmful object than the control mice did. These results are discussed in reference to the known lack of serotonin in the animals, and to the behavioral phenotype of DS.
doi_str_mv 10.1038/sj.npp.1300242
format Article
fullrecord <record><control><sourceid>pascalfrancis_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1038_sj_npp_1300242</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15318086</sourcerecordid><originalsourceid>FETCH-LOGICAL-c349t-cf6bdfe5190840b473300cf2e172422af9fd3276d8e5796f0ed7c81777487d5c3</originalsourceid><addsrcrecordid>eNp1kLtOwzAYhS0EEuWyMntha4odJ7HDVpVLkQpIFKRukWv_hlSpHdlpoQ_By_AgPBOuisTE5OE_37G-g9AZJQNKmLgIi4Ft2wFlhKRZuod6lGckKVg220c9IkqWUMZmh-gohAUhNOeF6KHPsfRLPFy7WkuroI-H9qOGbtPH0mr8BKF1NgDuHH5wa2i6Da4t7t4AD7VrICiwHZ4mlJDvL_zspQ2vYGuF790qwCV-ihnsDJ6Cd52zEd21NrDe_ratvXLvFk83Vnu3hBN0YGQT4PT3PUYvN9fPo3Eyeby9Gw0niWJZ2SXKFHNtIKclERmZZ5xFZ2VSoDyap9KURrOUF1pAzsvCENBcCco5zwTXuWLHaLDrVd6F4MFUra-X0m8qSqrtmFVYVHHM6nfMCJzvgFYGJRsTTVUd_qicUUFEEXMXu1yIJ_sKvlq4lbfR5b_mH6yBhwA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Harm Avoidance, Anxiety, and Response to Novelty in the Adolescent S-100β Transgenic Mouse: Role of Serotonin and Relevance to Down Syndrome</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Bell, Kimberly ; Shokrian, David ; Potenzieri, Carl ; Whitaker-Azmitia, Patricia M</creator><creatorcontrib>Bell, Kimberly ; Shokrian, David ; Potenzieri, Carl ; Whitaker-Azmitia, Patricia M</creatorcontrib><description>S-100 β is an astroglial-derived protein, which plays a role in brain development and maintenance, and is known to play a specific role in the regulation of growth of the serotonergic neuronal system. In humans, the gene for S-100 β is found on chromosome 21, within the region that is considered important for the phenotype of Down syndrome (DS). Thus, we have been studying a model of DS, the S-100 β transgenic mouse. In the current study, we have examined anxiety and responses to novelty in adolescent (60–90 days) animals, at a time when we have shown the animals to be relatively lacking in serotonin innervation, compared to their CD-1 nontransgenic controls. In a test for approach/avoidance, the light/dark test, the S-100 β transgenic mice animals showed no differences from control CD-1 mice. However, in the hole-board test for exploratory behavior, the S-100 β animals were found to be less responsive to the inhibiting effects of the serotonin receptor 5-HT1A agonist, buspirone. Three tests were used to measure response to novelty. In the open field, the S-100 β animals showed greater activity longer than the control animals, and in the Y-maze test, the S-100 β animals spent more time in the novel arm. In a test for novelty-induced gnawing, the S-100 β animals were also more active than control animals. All of these suggest that the S-100 β transgenic mice are slower to habituate to novelty than control animals. Finally, we tested the animals in a new procedure that we are proposing as a test for harm avoidance. In this apparatus, the S-100 β animals showed more approaches to a novel and potentially harmful object than the control mice did. These results are discussed in reference to the known lack of serotonin in the animals, and to the behavioral phenotype of DS.</description><identifier>ISSN: 0893-133X</identifier><identifier>EISSN: 1740-634X</identifier><identifier>DOI: 10.1038/sj.npp.1300242</identifier><identifier>CODEN: NEROEW</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Behavioral Sciences ; Biological and medical sciences ; Biological Psychology ; Chromosome aberrations ; Medical genetics ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Neurosciences ; original-article ; Pharmacotherapy ; Psychiatry</subject><ispartof>Neuropsychopharmacology (New York, N.Y.), 2003-10, Vol.28 (10), p.1810-1816</ispartof><rights>American College of Neuropsychopharmacology 2003</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c349t-cf6bdfe5190840b473300cf2e172422af9fd3276d8e5796f0ed7c81777487d5c3</citedby><cites>FETCH-LOGICAL-c349t-cf6bdfe5190840b473300cf2e172422af9fd3276d8e5796f0ed7c81777487d5c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/sj.npp.1300242$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/sj.npp.1300242$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15318086$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Bell, Kimberly</creatorcontrib><creatorcontrib>Shokrian, David</creatorcontrib><creatorcontrib>Potenzieri, Carl</creatorcontrib><creatorcontrib>Whitaker-Azmitia, Patricia M</creatorcontrib><title>Harm Avoidance, Anxiety, and Response to Novelty in the Adolescent S-100β Transgenic Mouse: Role of Serotonin and Relevance to Down Syndrome</title><title>Neuropsychopharmacology (New York, N.Y.)</title><addtitle>Neuropsychopharmacol</addtitle><description>S-100 β is an astroglial-derived protein, which plays a role in brain development and maintenance, and is known to play a specific role in the regulation of growth of the serotonergic neuronal system. In humans, the gene for S-100 β is found on chromosome 21, within the region that is considered important for the phenotype of Down syndrome (DS). Thus, we have been studying a model of DS, the S-100 β transgenic mouse. In the current study, we have examined anxiety and responses to novelty in adolescent (60–90 days) animals, at a time when we have shown the animals to be relatively lacking in serotonin innervation, compared to their CD-1 nontransgenic controls. In a test for approach/avoidance, the light/dark test, the S-100 β transgenic mice animals showed no differences from control CD-1 mice. However, in the hole-board test for exploratory behavior, the S-100 β animals were found to be less responsive to the inhibiting effects of the serotonin receptor 5-HT1A agonist, buspirone. Three tests were used to measure response to novelty. In the open field, the S-100 β animals showed greater activity longer than the control animals, and in the Y-maze test, the S-100 β animals spent more time in the novel arm. In a test for novelty-induced gnawing, the S-100 β animals were also more active than control animals. All of these suggest that the S-100 β transgenic mice are slower to habituate to novelty than control animals. Finally, we tested the animals in a new procedure that we are proposing as a test for harm avoidance. In this apparatus, the S-100 β animals showed more approaches to a novel and potentially harmful object than the control mice did. These results are discussed in reference to the known lack of serotonin in the animals, and to the behavioral phenotype of DS.</description><subject>Behavioral Sciences</subject><subject>Biological and medical sciences</subject><subject>Biological Psychology</subject><subject>Chromosome aberrations</subject><subject>Medical genetics</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Neurosciences</subject><subject>original-article</subject><subject>Pharmacotherapy</subject><subject>Psychiatry</subject><issn>0893-133X</issn><issn>1740-634X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNp1kLtOwzAYhS0EEuWyMntha4odJ7HDVpVLkQpIFKRukWv_hlSpHdlpoQ_By_AgPBOuisTE5OE_37G-g9AZJQNKmLgIi4Ft2wFlhKRZuod6lGckKVg220c9IkqWUMZmh-gohAUhNOeF6KHPsfRLPFy7WkuroI-H9qOGbtPH0mr8BKF1NgDuHH5wa2i6Da4t7t4AD7VrICiwHZ4mlJDvL_zspQ2vYGuF790qwCV-ihnsDJ6Cd52zEd21NrDe_ratvXLvFk83Vnu3hBN0YGQT4PT3PUYvN9fPo3Eyeby9Gw0niWJZ2SXKFHNtIKclERmZZ5xFZ2VSoDyap9KURrOUF1pAzsvCENBcCco5zwTXuWLHaLDrVd6F4MFUra-X0m8qSqrtmFVYVHHM6nfMCJzvgFYGJRsTTVUd_qicUUFEEXMXu1yIJ_sKvlq4lbfR5b_mH6yBhwA</recordid><startdate>20031001</startdate><enddate>20031001</enddate><creator>Bell, Kimberly</creator><creator>Shokrian, David</creator><creator>Potenzieri, Carl</creator><creator>Whitaker-Azmitia, Patricia M</creator><general>Springer International Publishing</general><general>Nature Publishing</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20031001</creationdate><title>Harm Avoidance, Anxiety, and Response to Novelty in the Adolescent S-100β Transgenic Mouse: Role of Serotonin and Relevance to Down Syndrome</title><author>Bell, Kimberly ; Shokrian, David ; Potenzieri, Carl ; Whitaker-Azmitia, Patricia M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c349t-cf6bdfe5190840b473300cf2e172422af9fd3276d8e5796f0ed7c81777487d5c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Behavioral Sciences</topic><topic>Biological and medical sciences</topic><topic>Biological Psychology</topic><topic>Chromosome aberrations</topic><topic>Medical genetics</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Neurosciences</topic><topic>original-article</topic><topic>Pharmacotherapy</topic><topic>Psychiatry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bell, Kimberly</creatorcontrib><creatorcontrib>Shokrian, David</creatorcontrib><creatorcontrib>Potenzieri, Carl</creatorcontrib><creatorcontrib>Whitaker-Azmitia, Patricia M</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bell, Kimberly</au><au>Shokrian, David</au><au>Potenzieri, Carl</au><au>Whitaker-Azmitia, Patricia M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Harm Avoidance, Anxiety, and Response to Novelty in the Adolescent S-100β Transgenic Mouse: Role of Serotonin and Relevance to Down Syndrome</atitle><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle><stitle>Neuropsychopharmacol</stitle><date>2003-10-01</date><risdate>2003</risdate><volume>28</volume><issue>10</issue><spage>1810</spage><epage>1816</epage><pages>1810-1816</pages><issn>0893-133X</issn><eissn>1740-634X</eissn><coden>NEROEW</coden><abstract>S-100 β is an astroglial-derived protein, which plays a role in brain development and maintenance, and is known to play a specific role in the regulation of growth of the serotonergic neuronal system. In humans, the gene for S-100 β is found on chromosome 21, within the region that is considered important for the phenotype of Down syndrome (DS). Thus, we have been studying a model of DS, the S-100 β transgenic mouse. In the current study, we have examined anxiety and responses to novelty in adolescent (60–90 days) animals, at a time when we have shown the animals to be relatively lacking in serotonin innervation, compared to their CD-1 nontransgenic controls. In a test for approach/avoidance, the light/dark test, the S-100 β transgenic mice animals showed no differences from control CD-1 mice. However, in the hole-board test for exploratory behavior, the S-100 β animals were found to be less responsive to the inhibiting effects of the serotonin receptor 5-HT1A agonist, buspirone. Three tests were used to measure response to novelty. In the open field, the S-100 β animals showed greater activity longer than the control animals, and in the Y-maze test, the S-100 β animals spent more time in the novel arm. In a test for novelty-induced gnawing, the S-100 β animals were also more active than control animals. All of these suggest that the S-100 β transgenic mice are slower to habituate to novelty than control animals. Finally, we tested the animals in a new procedure that we are proposing as a test for harm avoidance. In this apparatus, the S-100 β animals showed more approaches to a novel and potentially harmful object than the control mice did. These results are discussed in reference to the known lack of serotonin in the animals, and to the behavioral phenotype of DS.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><doi>10.1038/sj.npp.1300242</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0893-133X
ispartof Neuropsychopharmacology (New York, N.Y.), 2003-10, Vol.28 (10), p.1810-1816
issn 0893-133X
1740-634X
language eng
recordid cdi_crossref_primary_10_1038_sj_npp_1300242
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerLink Journals - AutoHoldings
subjects Behavioral Sciences
Biological and medical sciences
Biological Psychology
Chromosome aberrations
Medical genetics
Medical sciences
Medicine
Medicine & Public Health
Neurosciences
original-article
Pharmacotherapy
Psychiatry
title Harm Avoidance, Anxiety, and Response to Novelty in the Adolescent S-100β Transgenic Mouse: Role of Serotonin and Relevance to Down Syndrome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T02%3A27%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pascalfrancis_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Harm%20Avoidance,%20Anxiety,%20and%20Response%20to%20Novelty%20in%20the%20Adolescent%20S-100%CE%B2%20Transgenic%20Mouse:%20Role%20of%20Serotonin%20and%20Relevance%20to%20Down%20Syndrome&rft.jtitle=Neuropsychopharmacology%20(New%20York,%20N.Y.)&rft.au=Bell,%20Kimberly&rft.date=2003-10-01&rft.volume=28&rft.issue=10&rft.spage=1810&rft.epage=1816&rft.pages=1810-1816&rft.issn=0893-133X&rft.eissn=1740-634X&rft.coden=NEROEW&rft_id=info:doi/10.1038/sj.npp.1300242&rft_dat=%3Cpascalfrancis_cross%3E15318086%3C/pascalfrancis_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true